Adjanie Patabendige

ABC ATP binding cassette AD Alzheimer's disease AIDS acquired immune deficiency syndrome ApoE apolipoprotein E Aβ amyloid beta BACE1 beta-site amyloid precursor protein cleaving enzyme 1 (or beta secretase 1) BBB blood–brain barrier CARPA complement activation-related pseudoallergy CED convection enhanced delivery CNS central nervous system CSF cerebrospinal fluid DKK1 Dickkopf WNT Signaling Pathway Inhibitor 1 ECs endothelial cells EGCG epigallocatechin-3-gallate EPR enhanced permeability...

Introduction The blood–brain barrier (BBB) is often a primary factor that affects the viability of novel central nervous system (CNS) therapeutics. Lipinski’s rule of 5 has served in the past as a set of parameters that screen therapeutic candidates that can reach fluid compartments in the CNS (Lipinski et al., 2001; Bauer et al., 2014).